Episurf Medical announced that the abstract "Clinical results after treatment with a patient customised mini metal implant for focal cartilage damage in the knee", has been accepted for a podium presentation at the Swedish Orthopaedic Society's annual congress, which will take place in Malmö, Sweden, on August 29 - September 2, 2022. The presentation will be held by Prof. Karl Eriksson from Stockholm South Hospital and The Karolinska Institute, Stockholm, Sweden. The abstract reports on the clinical outcome for patients having undergone treatment with Episurf Medical's personalised knee implant Episealer® for treatment of isolated chondral and osteochondral defects in the knee, at Stockholm South Hospital.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.368 SEK | -7.65% | -48.10% | -62.83% |
Apr. 24 | Episurf Medical AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 22 | Episurf Medical Plans SEK120 Million Rights Issue | MT |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-62.83% | 9.79M | |
+12.59% | 128B | |
-10.58% | 10.66B | |
-0.39% | 8.55B | |
+13.56% | 7.1B | |
+25.94% | 5.06B | |
+6.93% | 3.4B | |
-1.64% | 3.08B | |
-11.96% | 2.11B | |
-7.25% | 2.03B |
- Stock Market
- Equities
- EPIS B Stock
- News Episurf Medical AB
- Episurf Medical Announces Results from Study with Episealer® Knee Implant Accepted for Presentation at Swedish Orthopaedic Congress